JDP Secures $17 Million in Series A Financing
June 28, 2016
JDP Enters Development and Supply Agreement with Hospira/Pfizer
March 24, 2016
JDP Announces Notice of Allowance for Two New Patents Covering JDP-205 and JDP-207.
July 20, 2015
JDP Announces Notice of Allowance for Its 4th Patent Covering JDP-205
May 15, 2015
JDP Successfully Completes Its Initial Phase 3 Clinical Trial of JDP-205 in Patients with Acute Urticaria Associated with an Acute Allergic Reaction.
January 8, 2015
JDP Therapeutics Inc. is a privately held, clinical Phase 3 stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.